The ras effector RASSF2 controls the PAR-4 tumor suppressor

Molecular and Cellular Biology

Volumn 30, Issue 11, 2010, Pages 2608-2620

  Donninger, Howard ^a   Hesson, Luke ^b   Vos, Michele ^c   Beebe, Kristin ^c   Gordon, Laura ^a   Sidransky, David ^d   Liu, Jun Wei ^d   Schlegel, Thomas ^e   Payne, Shannon ^e   Hartmann, Arndt ^f   Latif, Farida ^b   Clark, Geoffrey J ^a  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c NATIONAL CANCER INSTITUTE   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^f EPIGENOMICS AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

K RAS PROTEIN; NUCLEAR PROTEIN; PROSTATE APOPTOSIS RESPONSE PROTEIN 4; RASSF2 PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CELL; CYTOPLASM; EPIGENETICS; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MUTANT; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE TUMOR; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; APOPTOSIS REGULATORY PROTEINS; CELL NUCLEUS; CELLS, CULTURED; GENES, RAS; HUMANS; MALE; MIDDLE AGED; PROMOTER REGIONS, GENETIC; PROSTATE; PROSTATIC NEOPLASMS; RAS PROTEINS; RECOMBINANT FUSION PROTEINS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS; TWO-HYBRID SYSTEM TECHNIQUES;

EID: 77952589038     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.00208-09     Document Type: Article

References (49)

1. Akino, K., M. Toyota, H. Suzuki, H. Mita, Y. Sasaki, M. Ohe-Toyota, J. P. Issa, Y. Hinoda, K. Imai, and T. Tokino. 2005. The Ras effector RASSF2 is a novel tumor-suppressor gene in human colorectal cancer. Gastroenterology 129:156-169. (Pubitemid 41002052)
2. Boehrer, S., K. U. Chow, E. Puccetti, M. Ruthardt, S. Godzisard, A. Krapohl, B. Schneider, D. Hoelzer, P. S. Mitrou, V. M. Rangnekar, and E. Weidmann. 2001. Deregulated expression of prostate apoptosis response gene-4 in less differentiated lymphocytes and inverse expressional patterns of par-4 and bcl-2 in acute lymphocytic leukemia. Hematol. J. 2:103-107.
3. Boehrer, S., D. Nowak, E. Puccetti, M. Ruthardt, N. Sattler, B. Trepohl, B. Schneider, D. Hoelzer, P. S. Mitrou, and K. U. Chow. 2006. Prostate-apoptosis-response-gene-4 increases sensitivity to TRAIL-induced apoptosis. Leuk. Res. 30:597-605.
4. Calvisi, D. F., S. Ladu, A. Gorden, M. Farina, E. A. Conner, J. S. Lee, V. M. Factor, and S. S. Thorgeirsson. 2006. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology 130:1117-1128.
5. Chakraborty, M., S. G. Qiu, K. M. Vasudevan, and V. M. Rangnekar. 2001. Par-4 drives trafficking and activation of Fas and Fasl to induce prostate cancer cell apoptosis and tumor regression. Cancer Res. 61:7255-7263.
6. Cook, J., S. Krishnan, S. Ananth, S. F. Sells, Y. Shi, M. M. Walther, W. M. Linehan, V. P. Sukhatme, M. H. Weinstein, and V. M. Rangnekar. 1999. Decreased expression of the pro-apoptotic protein Par-4 in renal cell carcinoma. Oncogene 18:1205-1208.
7. Cooper, W. N., R. E. Dickinson, A. Dallol, E. V. Grigorieva, T. V. Pavlova, L. B. Hesson, I. Bieche, M. Broggini, E. R. Maher, E. R. Zabarovsky, G. J. Clark, and F. Latif. 2008. Epigenetic regulation of the ras effector/tumour suppressor RASSF2 in breast and lung cancer. Oncogene 27:1805-1811.
8. Cooper, W. N., L. B. Hesson, D. Matallanas, A. Dallol, A. von Kriegsheim, R. Ward, W. Kolch, and F. Latif. 2009. RASSF2 associates with and stabilizes the proapoptotic kinase MST2. Oncogene 28:2988-2998.
9. Cottrell, S. E., J. Distler, N. S. Goodman, S. H. Mooney, A. Kluth, A. Olek, I. Schwope, R. Tetzner, H. Ziebarth, and K. Berlin. 2004. A real-time PCR assay for DNA-methylation using methylation-specific blockers. Nucleic Acids Res. 32:e10.
10. Cox, A. D., and C. J. Der. 2003. The dark side of Ras: regulation of apoptosis. Oncogene 22:8999-9006.
11. Diaz-Meco, M. T., M. M. Municio, S. Frutos, P. Sanchez, J. Lozano, L. Sanz, and J. Moscat. 1996. The product of par-4, a gene induced during apoptosis, interacts selectively with the atypical isoforms of protein kinase C. Cell 86:777-786.
12. Donninger, H., M. D. Vos, and G. J. Clark. 2007. The RASSF1A tumor suppressor. J. Cell Sci. 120:3163-3172.
13. Downward, J. 2003. Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer 3:11-22.
14. Eads, C. A., R. V. Lord, K. Wickramasinghe, T. I. Long, S. K. Kurumboor, L. Bernstein, J. H. Peters, S. R. DeMeester, T. R. DeMeester, K. A. Skinner, and P. W. Laird. 2001. Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res. 61:3410-3418.
15. El-Guendy, N., Y. Zhao, S. Gurumurthy, R. Burikhanov, and V. M. Rangnekar. 2003. Identification of a unique core domain of par-4 sufficient for selective apoptosis induction in cancer cells. Mol. Cell. Biol. 23:5516-5525.
16. Endoh, M., G. Tamura, T. Honda, N. Homma, M. Terashima, S. Nishizuka, and T. Motoyama. 2005. RASSF2, a potential tumour suppressor, is silenced by CpG island hypermethylation in gastric cancer. Br. J. Cancer 93:1395-1399. (Pubitemid 41752867)
17. Fenton, S. L., A. Dallol, A. Agathanggelou, L. Hesson, J. Ahmed-Choudhury, S. Baksh, C. Sardet, R. Dammann, J. D. Minna, J. Downward, E. R. Maher, and F. Latif. 2004. Identification of the E1A-regulated transcription factor p120 E4F as an interacting partner of the RASSF1A candidate tumor suppressor gene. Cancer Res. 64:102-107.
18. Fiordalisi, J. J., R. L. Johnson II, A. S. Ulku, C. J. Der, and A. D. Cox. 2001. Mammalian expression vectors for Ras family proteins: generation and use of expression constructs to analyze Ras family function. Methods Enzymol. 332:3-36.
19. Garcia-Cao, I., A. Duran, M. Collado, M. J. Carrascosa, J. Martin-Caballero, J. M. Flores, M. T. Diaz-Meco, J. Moscat, and M. Serrano. 2005. Tumour-suppression activity of the proapoptotic regulator Par4. EMBO Rep. 6:577-583. (Pubitemid 40973968)
20. Garcia-Cao, I., M. J. Lafuente, L. M. Criado, M. T. Diaz-Meco, M. Serrano, and J. Moscat. 2003. Genetic inactivation of Par4 results in hyperactivation of NF-κB and impairment of JNK and p38. EMBO Rep. 4:307-312. (Pubitemid 36511729)
21. Goswami, A., R. Burikhanov, A. de Thonel, N. Fujita, M. Goswami, Y. Zhao, J. E. Eriksson, T. Tsuruo, and V. M. Rangnekar. 2005. Binding and phosphorylation of par-4 by akt is essential for cancer cell survival. Mol. Cell 20:33-44.
22. Guo, C., S. Tommasi, L. Liu, J. K. Yee, R. Dammann, and G. P. Pfeifer. 2007. RASSF1A is part of a complex similar to the Drosophila Hippo/Salvador/Lats tumor-suppressor network. Curr. Biol. 17:700-705.
23. Gurumurthy, S., A. Goswami, K. M. Vasudevan, and V. M. Rangnekar. 2005. Phosphorylation of Par-4 by protein kinase A is critical for apoptosis. Mol. Cell. Biol. 25:1146-1161.
24. Hesson, L. B., R. Wilson, D. Morton, C. Adams, M. Walker, E. R. Maher, and F. Latif. 2005. CpG island promoter hypermethylation of a novel Raseffector gene RASSF2A is an early event in colon carcinogenesis and correlates inversely with K-ras mutations. Oncogene 24:3987-3994.
25. Imai, T., M. Toyota, H. Suzuki, K. Akino, K. Ogi, Y. Sogabe, L. Kashima, R. Maruyama, M. Nojima, H. Mita, Y. Sasaki, F. Itoh, K. Imai, Y. Shinomura, H. Hiratsuka, and T. Tokino. 2008. Epigenetic inactivation of RASSF2 in oral squamous cell carcinoma. Cancer Sci. 99:958-966.
26. Joshi, J., P. J. Fernandez-Marcos, A. Galvez, R. Amanchy, J. F. Linares, A. Duran, P. Pathrose, M. Leitges, M. Canamero, M. Collado, C. Salas, M. Serrano, J. Moscat, and M. T. Diaz-Meco. 2008. Par-4 inhibits Akt and suppresses Ras-induced lung tumorigenesis. EMBO J. 27:2181-2193.
27. Kaira, K., N. Sunaga, Y. Tomizawa, N. Yanagitani, T. Ishizuka, R. Saito, T. Nakajima, and M. Mori. 2007. Epigenetic inactivation of the RAS-effector gene RASSF2 in lung cancers. Int. J. Oncol. 31:169-173.
28. Khokhlatchev, A., S. Rabizadeh, R. Xavier, M. Nedwidek, T. Chen, X. F. Zhang, B. Seed, and J. Avruch. 2002. Identification of a novel Ras-regulated proapoptotic pathway. Curr. Biol. 12:253-265.
29. Kumari, G., P. K. Singhal, M. R. Rao, and S. Mahalingam. 2007. Nuclear transport of Ras-associated tumor suppressor proteins: different transport receptor binding specificities for arginine-rich nuclear targeting signals. J. Mol. Biol. 367:1294-1311.
30. Liu, J. W., J. K. Nagpal, C. Jeronimo, J. E. Lee, R. Henrique, M. S. Kim, K. L. Ostrow, K. Yamashita, V. van Criekinge, G. Wu, C. S. Moon, B. Trink, and D. Sidransky. 2008. Hypermethylation of MCAM gene is associated with advanced tumor stage in prostate cancer. Prostate 68:418-426.
31. Malumbres, M., and M. Barbacid. 2003. RAS oncogenes: the first 30 years. Nat. Rev. Cancer 3:459-465.
32. Maruyama, R., K. Akino, M. Toyota, H. Suzuki, T. Imai, M. Ohe-Toyota, E. Yamamoto, M. Nojima, T. Fujikane, Y. Sasaki, T. Yamashita, Y. Watanabe, H. Hiratsuka, K. Hirata, F. Itoh, K. Imai, Y. Shinomura, and T. Tokino. 2008. Cytoplasmic RASSF2A is a proapoptotic mediator whose expression is epigenetically silenced in gastric cancer. Carcinogenesis 29:1312-1318.
33. Model, F., N. Osborn, D. Ahlquist, R. Gruetzmann, B. Molnar, F. Sipos, O. Galamb, C. Pilarsky, H. D. Saeger, Z. Tulassay, K. Hale, S. Mooney, J. Lograsso, P. Adorjan, R. Lesche, A. Dessauer, J. Kleiber, B. Porstmann, A. Sledziewski, and C. Lofton-Day. 2007. Identification and validation of colorectal neoplasia-specific methylation markers for accurate classification of disease. Mol. Cancer Res. 5:153-163.
34. Moreno-Bueno, G., P. J. Fernandez-Marcos, M. Collado, M. J. Tendero, S. M. Rodriguez-Pinilla, I. Garcia-Cao, D. Hardisson, M. T. Diaz-Meco, J. Moscat, M. Serrano, and J. Palacios. 2007. Inactivation of the candidate tumor suppressor par-4 in endometrial cancer. Cancer Res. 67:1927-1934. (Pubitemid 46424208)
35. Nalca, A., S. G. Qiu, N. El-Guendy, S. Krishnan, and V. M. Rangnekar. 1999. Oncogenic Ras sensitizes cells to apoptosis by Par-4. J. Biol. Chem. 274: 29976-29983.
36. Park, H. W., H. C. Kang, I. J. Kim, S. G. Jang, K. Kim, H. J. Yoon, S. Y. Jeong, and J. G. Park. 2007. Correlation between hypermethylation of the RASSF2A promoter and K-ras/BRAF mutations in microsatellite-stable colorectal cancers. Int. J. Cancer 120:7-12.
37. Pearson, H. B., T. J. Phesse, and A. R. Clarke. 2009. K-ras and Wnt signaling synergize to accelerate prostate tumorigenesis in the mouse. Cancer Res. 69:94-101.
38. Pruitt, K., A. S. Ulku, K. Frantz, R. J. Rojas, V. M. Muniz-Medina, V. M. Rangnekar, C. J. Der, and J. M. Shields. 2005. Ras-mediated loss of the pro-apoptotic response protein Par-4 is mediated by DNA hypermethylation through Raf-independent and Raf-dependent signaling cascades in epithelial cells. J. Biol. Chem. 280:23363-23370.
39. Qiu, G., M. Ahmed, S. F. Sells, M. Mohiuddin, M. H. Weinstein, and V. M. Rangnekar. 1999. Mutually exclusive expression patterns of Bcl-2 and Par-4 in human prostate tumors consistent with down-regulation of Bcl-2 by Par-4. Oncogene 18:623-631.
40. Sells, S. F., S. S. Han, S. Muthukkumar, N. Maddiwar, R. Johnstone, E. Boghaert, D. Gillis, G. Liu, P. Nair, S. Monnig, P. Collini, M. P. Mattson, V. P. Sukhatme, S. G. Zimmer, D. P. Wood, Jr., J. W. McRoberts, Y. Shi, and V. M. Rangnekar. 1997. Expression and function of the leucine zipper protein Par-4 in apoptosis. Mol. Cell. Biol. 17:3823-3832.
41. Sells, S. F., D. P. Wood, Jr., S. S. Joshi-Barve, S. Muthukumar, R. J. Jacob, S. A. Crist, S. Humphreys, and V. M. Rangnekar. 1994. Commonality of the gene programs induced by effectors of apoptosis in androgen-dependent and -independent prostate cells. Cell Growth Differ. 5:457-466.
42. Shareef, M. M., N. Cui, R. Burikhanov, S. Gupta, S. Satishkumar, S. Shajahan, M. Mohiuddin, V. M. Rangnekar, and M. M. Ahmed. 2007. Role of tumor necrosis factor-alpha and TRAIL in high-dose radiation-induced bystander signaling in lung adenocarcinoma. Cancer Res. 67:11811-11820.
43. Tommasi, S., R. Dammann, Z. Zhang, Y. Wang, L. Liu, W. M. Tsark, S. P. Wilczynski, J. Li, M. You, and G. P. Pfeifer. 2005. Tumor susceptibility of Rassf1a knockout mice. Cancer Res. 65:92-98. (Pubitemid 40070799)
44. van der Weyden, L., and D. J. Adams. 2007. The Ras-association domain family (RASSF) members and their role in human tumourigenesis. Biochim. Biophys. Acta 1776:58-85.
45. Vos, M. D., A. Dallol, K. Eckfeld, N. P. Allen, H. Donninger, L. B. Hesson, D. Calvisi, F. Latif, and G. J. Clark. 2006. The RASSF1A tumor suppressor activates Bax via MOAP-1. J. Biol. Chem. 281:4557-4563.
46. Vos, M. D., C. A. Ellis, A. Bell, M. J. Birrer, and G. J. Clark. 2000. Ras uses the novel tumor suppressor RASSF1 as an effector to mediate apoptosis. J. Biol. Chem. 275:35669-35672.
47. Vos, M. D., C. A. Ellis, C. Elam, A. S. Ulku, B. J. Taylor, and G. J. Clark. 2003. RASSF2 is a novel K-Ras-specific effector and potential tumor suppressor. J. Biol. Chem. 278:28045-28051.
48. Zhang, Z., D. Sun, N. Van do, A. Tang, L. Hu, and G. Huang. 2007. Inactivation of RASSF2A by promoter methylation correlates with lymph node metastasis in nasopharyngeal carcinoma. Int. J. Cancer. 120:32-38.
49. Zhao, Y., R. Burikhanov, S. Qiu, S. M. Lele, C. D. Jennings, S. Bondada, B. Spear, and V. M. Rangnekar. 2007. Cancer resistance in transgenic mice expressing the SAC module of Par-4. Cancer Res. 67:9276-9285.